Inovio Pharmaceuticals Reports 2015 Fourth Quarter and Year End Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Maxim Affirms Inovio Pharma (INO) at 'Buy' Following Q4 Results, Asset Acquisition
March 14, 2016 2:45 PM EDTMaxim affirmed Inovio Pharma (Nasdaq: INO) with a Buy rating and $14 price target following Q4 results and acquisition of Bioject Medical Technologies' Needle-Free Injection Technology earlier Monday.
Analyst Jason Kolbert noted the following
Immune oncology: A phase III study for VGX-3100 is expected... More